Navigation Links
Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
Date:12/3/2007

lity of this novel compound as a new therapeutic option for patients affected by hypertension and related disorders such as diabetic nephropathy," stated Rene Belder, M.D., Pharmacopeia's Vice President of Clinical and Regulatory Affairs. "We look forward to the completion of our ongoing Phase 2a study in the first half of 2008 and hope to see the first clear demonstration of the compound's potential efficacy in hypertensive patients."

PS433540 is a dual-acting angiotensin (AII) and endothelin (ET1) receptor antagonist that is being developed as a potential treatment for hypertension and diabetic nephropathy. PS433540, the first and only DARA compound in development, possesses two clinically validated mechanisms of action in a single compound. There is considerable preclinical and initial clinical data suggesting that compared to either agent alone, simultaneously blocking the actions of both AII and ET1 may provide significantly improved treatment options for several cardiovascular diseases.

ABOUT PHARMACOPEIA

Pharmacopeia is a clinical development stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics to address significant medical needs. The company has a broad portfolio of clinical and preclinical candidates under development internally or by partners including seven clinical compounds in Phase 2 or Phase 1 development addressing multiple indications including hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The company is leveraging its fully integrated drug discovery platform to sustain the growth of its development pipeline. Pharmacopeia has established strategic agreements with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Organon, Schering-Plough, and Wyeth Pharmaceuticals. For more information please visit the company's website at h
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
2. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
3. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
4. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
5. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
6. Pharmacopeia Announces Third Quarter 2007 Financial Results
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... Calif. , Oct. 17, 2014 A victim ... Orange County doctor with a history of alcohol ... ad for Yes on Prop 46 today, highlighting how Prop ... drug and alcohol testing. The ad pictures ... off reading "911-Report To ER."  Proposition 46 will enact the ...
(Date:10/17/2014)... , Oct. 17, 2014  UBM Medica US announces ... for endocrinologists and other clinicians who treat patients with ... on effective use of insulin .  ... insulin replacement therapy – daily injections of ... progressive decline in the function of pancreatic beta cells. ...
(Date:10/17/2014)... 17, 2014   ndd Medical Technologies , a ... precise ultrasound technology, announced that its EasyOne Pro® is ... Center , a 140,000 square foot, 44-bed hospital with ... hospital serves a large number of Native Americans ... and beyond. A portion of its funding ...
Breaking Medicine Technology:Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 2Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 4Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3EasyOne Pro Mobile Respiratory Testing from ndd Medical Technologies Chosen by Choctaw Nation 2
... Delcath Systems, Inc. (Nasdaq: DCTH ) today announced ... Directors. Dr. Contag is a proven corporate executive with extensive ... , (LOGO: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO ) ... Technologies, Inc. in 2006 and served as CEO. Prior to ...
... (NTI(R)) (Nasdaq: NTII ) today announced ... determined that the current clinical,trials of Viprinex(TM) for ... show benefit. As a result, the company has ... and analyze the data before evaluating the,potential for ...
Cached Medicine Technology:Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 2Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 3Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis 2
(Date:10/20/2014)... 20, 2014 T.E.N., a technology ... announced today that William H. Murray, renowned author ... ISE® Luminary Leadership Award winner. Presented annually, the ... an outstanding leader and industry practitioner for his ... advancing the information security industry. , Formerly with ...
(Date:10/20/2014)... October 20, 2014 JZ Fitness, an ... coaching, corporate wellness programming, authorship, international lecturing and community ... to announce the release of the JZ Fitness nutrition ... years of coaching thousands of individuals on nutrition, Jenn ... that does not require calorie counting or cumbersome food ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 AttorneyOne.com, a recognized ... latest information from the FDA on Sit and Slim ... 10 not to purchase or use Sit and Slim II ... Slim II is promoted as weight loss product on various ... from the market in 2010 for safety reasons, can significantly ...
(Date:10/20/2014)... October 20, 2014 Succeed is proud to ... companies who participated in the Every Body Walk! ... public awareness project that encourages workers to be more active ... 10,000 Program, which concluded at the end of September, was ... cities and metro areas. Participating companies gave their staff ...
(Date:10/20/2014)... Aliso Viejo, California (PRWEB) October 20, 2014 ... have announced the release of the Citrus theme for ... words I would use to describe the Citrus theme” Says ... been so easy to look so professional.” , Citrus comes ... . Included with the template are: four transitions for added ...
Breaking Medicine News(10 mins):Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2
... Those who ate right, exercised lowered chances of cardiovascular trouble ... advice about eating the right foods, exercising and losing weight ... two new studies show. , The reports, both originating at ... July 22/29 issue of the Journal of the American ...
... , NEW YORK, July 21 The notice ... class action involves MetLife,s April 2000 conversion from a mutual insurance ... the Federal Court in New York includes more than 8.6 million ... The notice of the class action will be mailed to ...
... NEW YORK, July 21 The Michael J. ... nine biotech and pharmaceutical companies a total of $3.8 million ... push forward novel neuroprotective and improved symptomatic therapies as well ... , While MJFF accepts applications from ...
... could lead to better therapies for severe forms of the ... the University of Texas Southwestern Medical Center have figured what ... when he or she has a severe staph infection. , ... infections but applicable to all people, could lead to ...
... of amniotic and cervical fluids yields clues to early birth ... panel of proteins in amniotic and cervical fluids might enable ... birth prematurely. , No such test exists now. If perfected, ... can determine which women face a lower risk of delivering ...
... , Organizations are recognized ... disease prevention , , ... week that it has awarded the prestigious C. Everett Koop ... their health promotion and disease prevention programs have improved the ...
Cached Medicine News:Health News:Studies Affirm Value of Healthy Lifestyle 2Health News:Studies Affirm Value of Healthy Lifestyle 3Health News:Notice Begins Announcing Pendency of a Class Action Regarding MetLife 2Health News:Notice Begins Announcing Pendency of a Class Action Regarding MetLife 3Health News:Michael J. Fox Foundation Awards $3.8 Million To Drive Nine Industry Partnerships For Pre-Clinical Parkinson's Drug Development 2Health News:Michael J. Fox Foundation Awards $3.8 Million To Drive Nine Industry Partnerships For Pre-Clinical Parkinson's Drug Development 3Health News:Immune System Gene Discovery Sheds Light on Staph Infections 2Health News:Test May Predict Moms Who Will Deliver Prematurely 2Health News:Test May Predict Moms Who Will Deliver Prematurely 3Health News:Winners of the C. Everett Koop Health Project Award Announced 2
... line has the right product for any ... from intubated patients to patients with tracheotomies. ... anesthesia and critical care applications., ,The ... for patients and staff members. This entire ...
... Ulti-Mist™ HME product line has the right ... to adults and from intubated patients to ... humidification for both anesthesia and critical care ... provide maximum protection for patients and staff ...
... These hygroscopic condenser humidifiers (HCH) capture the ... them in the inspired gas. Small and ... bacteriostatic and hygroscopic benefits. Depending on the ... or small-volume model., ,The adult HCH ...
Combination heat and moisture exchanger and bacterial/viral filters for Anesthesia and Respiratory applications....
Medicine Products: